| Dec'17 | Dec'16 | |||||
|---|---|---|---|---|---|---|
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | ||||||
165,629 | 39,649 | |||||
Short term investments (note 4) | ||||||
7,833 | 0 | |||||
Accounts receivable | ||||||
109 | 86 | |||||
Prepaid expenses and deposits | ||||||
1,681 | 1,683 | |||||
Current assets | ||||||
175,252 | 41,418 | |||||
Clinical trial contract deposits | ||||||
448 | 0 | |||||
Property and equipment (note 5) | ||||||
31 | 29 | |||||
Acquired intellectual property and other intangible assets (note 6) | ||||||
14,116 | 15,550 | |||||
Assets | ||||||
189,847 | 56,997 | |||||
Liabilities | ||||||
Current liabilities | ||||||
Accounts payable and accrued liabilities (note 7) | ||||||
7,959 | 5,791 | |||||
Current portion of deferred revenue (note 8) | ||||||
118 | 118 | |||||
Contingent consideration (note 9) | ||||||
73 | 2,021 | |||||
Current liabilities | ||||||
8,150 | 7,930 | |||||
Deferred revenue (note 8) | ||||||
442 | 560 | |||||
Contingent consideration (note 9) | ||||||
3,719 | 3,419 | |||||
Derivative warrant liabilities (note 10) | ||||||
11,793 | 9,138 | |||||
Liabilities | ||||||
24,104 | 21,047 | |||||
Shareholders Equity | ||||||
Share capital | ||||||
Common shares (note 11) | ||||||
499,200 | 299,815 | |||||
Warrants (note 11) | ||||||
906 | 971 | |||||
Contributed surplus | ||||||
18,360 | 17,017 | |||||
Accumulated other comprehensive loss | ||||||
-883 | -805 | |||||
Deficit | ||||||
-351,840 | -281,048 | |||||
Equity | ||||||
165,743 | 35,950 | |||||
Equity and liabilities | ||||||
189,847 | 56,997 | |||||
Commitments and contingencies (note 19) | ||||||
0 | 0 | |||||